Today: 30 June 2026
KLA stock price whipsaws ahead of Jan. 29 earnings as Intel rattles chip sector

KLA stock price whipsaws ahead of Jan. 29 earnings as Intel rattles chip sector

New York, Jan 24, 2026, 17:09 ET — Market closed.

  • KLA closed Friday roughly 0.9% higher following a volatile session, hovering close to its 52-week peak
  • Investors are eyeing KLAC’s January 29 earnings report for clues on chipmaking investment and tool demand.
  • Intel’s steep slide on Friday left the semiconductor sector on edge heading into next week

KLA Corp (KLAC.O) shares closed Friday up around 0.9% at $1,512.78, swinging within a roughly 4% intraday range and falling more than 3% at one stage. The stock sits about 4% under its 52-week high, setting a tight range ahead of earnings.

With Wall Street closed for the weekend, focus turns to Monday’s open and the week’s key corporate update. KLA plans to release its fiscal second-quarter results Thursday, Jan. 29 at 2 p.m. PT, after markets have closed.

KLA’s timing is crucial because it operates in process control—the inspection and measurement tools chipmakers rely on to spot defects early and maintain yields as chips shrink. The company’s last forecast called for December-quarter revenue of $3.225 billion, with a $150 million margin on either side, and non-GAAP diluted EPS of $8.70, plus or minus $0.78. (Non-GAAP figures exclude certain items companies say can obscure true performance.)

Friday’s trading highlighted the sector’s jitteriness. The iShares Semiconductor ETF dropped roughly 1.1%, despite Applied Materials climbing 1.1%. Lam Research slid 1.3%, and ASML dipped 0.4%.

Intel sparked much of that jitters, with its shares plunging roughly 17% on Friday following a disappointing outlook. CEO Lip-Bu Tan warned investors the recovery would demand “time and resolve.” Investors.com

Broker targets for KLA have shifted, but not uniformly. New Street Research bumped its price target to $1,315 from $1,230, yet maintained a neutral rating, per a MarketBeat report. That target still sits below Friday’s closing price.

JPMorgan analysts, with Harlan Sur at the helm, have been advising clients to brace for a generally strong earnings season, anticipating “in-line/better” results alongside upbeat outlooks, TheStreet reported. They also highlighted KLA as a key player linked to the AI expansion. TheStreet

KLA provides inspection and metrology systems, along with software, used inside wafer-fab and packaging lines. Investors frequently view its guidance as a barometer for customer activity in cutting-edge production and whether that demand extends into memory and advanced packaging sectors.

Next week, attention will center less on raw numbers and more on guidance and tone. Traders will watch closely for any changes in demand from major foundry and memory clients, as well as updates on export controls and China exposure — a key swing factor for U.S. chip equipment firms.

The setup works both ways. KLAC’s stock sits near its highs, but any weaker guidance, margin squeeze, or hints of customer delays could weigh on the shares fast—especially if chip sector sentiment remains shaky.

Markets will reopen Monday, Jan. 26. KLA’s earnings report drops after Thursday’s close, with the conference call set for 2 p.m. PT.

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors.

Stock Market Today

  • SELLAS Life Sciences (NASDAQ:SLS) Drops 7.77% After 8-K Filing Ahead of REGAL Data
    June 30, 2026, 10:28 AM EDT. SELLAS Life Sciences shares dropped 7.77% to $14.25 on Tuesday after an 8-K showing senior management agreements and as the market waits for Phase 3 REGAL data on galinpepimut-S in AML. The study is approaching a milestone with 78 of 80 survival events, making some investors cautious. The stock recently hit a 52-week high of $15.67, but resistance is holding there with support at the 20-day simple moving average around $8.87. Technicals are flashing overbought with the RSI at 85.19, which could mean sharper pullbacks. SELLAS works on cancer therapies including GPS and CDK9 drugs, tying its shares to updates around leadership moves and clinical trials.
Exxon stock price: XTO’s Eagle Ford sale push puts XOM in play ahead of key week
Previous Story

Exxon stock price: XTO’s Eagle Ford sale push puts XOM in play ahead of key week

AAPL stock jumps nearly 3% as Morgan Stanley flags iPhone 17 strength ahead of Apple earnings
Next Story

AAPL stock jumps nearly 3% as Morgan Stanley flags iPhone 17 strength ahead of Apple earnings

Go toTop